Mediator complex component MED13 regulates zygotic genome activation and is required for postimplantation development in the mouse by Miao, Yi Liang et al.
Biology of Reproduction, 2018, 0(0), 1–16
doi:10.1093/biolre/ioy004
Research Article
Advance Access Publication Date: 9 January 2018
Research Article
Mediator complex component MED13 regulates
zygotic genome activation and is required for
postimplantation development in the mouse†,‡
Yi-Liang Miao1,2,∗, Andrés Gambini1, Yingpei Zhang1,
Elizabeth Padilla-Banks1, Wendy N Jefferson1, Miranda L Bernhardt1,
Weichun Huang3, Leping Li3 and Carmen J Williams1,∗
1Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, National
Institutes of Health, Research Triangle Park, North Carolina, USA; 2Key Laboratory of Agricultural Animal Genetics,
Breeding, and Reproduction, Ministry of Education College of Animal Science and Technology, Huazhong Agricultural
University, China and 3Biostatistics and Computational Biology Branch, National Institute of Environmental Health
Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA
∗Correspondence: Carmen J Williams: Reproductive and Developmental Biology Laboratory, National Institute of
Environmental Health Sciences, National Institutes of Health, PO Box 12233, MD E4-05, Research Triangle Park, NC 27709,
USA. Tel: +919-541-2158; Fax: +301-480-2732; E-mail: williamsc5@niehs.nih.gov; Yi-Liang Miao: Key Laboratory of
Agricultural Animal Genetics, Breeding, and Reproduction, Ministry of Education College of Animal Science and
Technology, Huazhong Agricultural University, 1 Shizishan St, Hongshan District, Wuhan, Hubei Province 430070, China.
Tel: +86-151-7238-1596; Fax: +86-278-728-2019; E-mail: miaoyl@mail.hzau.edu.cn
†Grant Support: This work was supported by National Natural Science Foundation of China (Grant No. 31471350 to Y-LM)
and the Intramural Research Program of the National Institutes of Health, National Institutes of Environmental Health
Sciences (1ZIAES102985 to CJW, 1ZIAES101765 to LL).
‡Accession Number: RNA sequencing data were deposited in the NCBI GEO database, accession number GSE90710.
Received 18 October 2017; Revised 22 December 2017; Accepted 8 January 2018
Abstract
Understanding factors that regulate zygotic genome activation (ZGA) is critical for determining
how cells are reprogrammed to become totipotent or pluripotent. There is limited information
regarding how this process occurs physiologically in early mammalian embryos. Here, we identify a
mediator complex subunit, MED13, as translated during mouse oocyte maturation and transcribed
early from the zygotic genome. Knockdown and conditional knockout approaches demonstrate
that MED13 is essential for ZGA in the mouse, in part by regulating expression of the embryo-
specific chromatin remodeling complex, esBAF. The role of MED13 in ZGA is mediated in part by
interactions with E2F transcription factors. In addition to MED13, its paralog, MED13L, is required
for successful preimplantation embryo development. MED13L partially compensates for loss of
MED13 function in preimplantation knockout embryos, but postimplantation development is not
rescued by MED13L. Our data demonstrate an essential role for MED13 in supporting chromatin
reprogramming and directed transcription of essential genes during ZGA.
Summary Sentence
MED13 is required for activating transcription of essential genes during the maternal to zygotic
transition in the mouse.
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Introduction
The “oocyte-to-embryo transition” (OET) encompasses a series of
tightly orchestrated developmental events that convert the prophase
I-arrested, germinal vesicle-intact oocyte (GV oocyte) through mat-
uration to metaphase II (MII) and then fertilization to become a
totipotent, transcriptionally active cleavage stage embryo. Because
GV oocytes are transcriptionally quiescent once fully grown, most
of these events depend on cytoplasmic factors generated and stored
during the oocyte growth phase. A key process regulating the OET is
temporally controlled polyadenylation and recruitment to polysomes
of stored dormant maternal mRNAs that encode proteins critical for
the success of preimplantation embryo development [1, 2]. These
proteins include requisite components for DNA replication such
as CDC6 and ORC6L, proteins required for chromatin remod-
eling such as SIN3A, histone H3.3 and histone H3 methyltrans-
ferase ASH2L, and mRNA-degrading enzymes including DCP1A
and DCP2 [3–9]. Waiting for oocyte maturation to begin generat-
ing these key proteins accomplishes at least two goals: (1) limited
oocyte resources are not wasted generating proteins not yet needed,
and (2) lack of these proteins prevents precocious DNA replication,
chromatin reprogramming, and mRNA degradation prior to fertil-
ization.
There is limited information regarding how embryonic gene tran-
scription is initiated during the OET in mammals. Data from ze-
brafish and Drosophila have led to a model of embryonic genome ac-
tivation in which “pioneer” transcription factors bind specific DNA
sequence motifs in gene-regulatory regions of genes important during
early genome activation. DNA occupancy by these transcription fac-
tors leads to recruitment of chromatin remodeling complexes, nucle-
osome repositioning and histone modifications, and subsequent re-
cruitment of RNA polymerase to the transcription start sites of these
genes [10]. In the mouse, embryonic genome activation begins at the
one-cell (1C; zygote) stage; hence, the term “zygotic genome activa-
tion” (ZGA) is used in this species. During this first wave of genome
activation, there is promiscuous transcription of numerous retro-
transposons, but relatively few protein-coding genes are transcribed
[11, 12]. Many critical factors driving zygotic transcription are ma-
ternally encoded [13]. For example, tripartite motif-containing pro-
tein 24 (TRIM24) is a maternally generated general transcription
regulator located in the oocyte cytoplasm that translocates into the
zygote pronuclei where it supports the first wave of transcription
[14]. In contrast to the dearth of information regarding factors that
support the onset of genome activation in pronuclear stage embryos,
recent reports have described several transcription factors essential
for the major wave of transcription that occurs in the two-cell (2C)
stage embryo, including DUX, ZSCAN, YAP1, and NFYα (reviewed
in [15]).
The mediator complex is an extremely large, multiprotein com-
plex that serves to link regulatory information from transcription
factors to RNA polymerase II and is conserved from yeast to human
(reviewed in [16]). A key role for mediator is to facilitate assem-
bly of the preinitiation complex, in part by serving as an adapter
between DNA-binding transcription factors at enhancers and RNA
polymerase II at promoters. Mediator is comprised of three modules
(head, middle, and tail) that make up the “core” mediator com-
plex and a kinase domain that is variably associated with the core
complex. The kinase domain was initially thought to serve only as
a transcriptional repressor, but more recent studies have demon-
strated that it also functions in context-dependent transcriptional
activation (reviewed in [17]). Transcriptional activation may be car-
ried out via kinase domain-mediated phosphorylation of enhancer-
associated transcription factors or coactivators [18]. The kinase
domain has four protein components: MED13, mediator complex
subunit 12 (MED12), cyclin C (CCNC), and cyclin-dependent ki-
nase 8 (CDK8). Three of the kinase domain proteins have paralogs
(MED12L, MED13L, and CDK19) that can replace their cognate
proteins in the kinase domain but do not appear to have complete
functional redundancy [19].
Fully grown GV oocytes and MII eggs are transcriptionally quies-
cent, so mediator function is not required at these stages, but media-
tor would be essential for RNA polymerase II-mediated transcription
of embryonic genes after fertilization. We reasoned that components
of the mediator complex would be good candidates to serve as pro-
teins recruited for translation during oocyte maturation and/or egg
activation as part of the developmentally programmed ZGA path-
way. Here, we show using both knockdown and conditional knock-
out approaches that the mediator complex component MED13 is a
critical upstream regulator of ZGA, and that its paralog, MED13L,
can partially compensate for its function.
Materials and methods
Animals and chemicals
The following mouse strains were used: CF-1 (Envigo, Indianapolis,
IN); B6SJLF1/J, C57Bl6/J, and Zp3-Cre [20] (Jackson Laborato-
ries, Bar Harbor, ME); Med13f/f [21]; and Hspa2-Cre [22]. Mice
were housed in a temperature-controlled environment under a 12 h
light:12 h dark cycle. All animal procedures complied with National
Institutes of Health animal care guidelines under an approved proto-
col. Chemicals were purchased from Sigma-Aldrich (St. Louis, MO)
unless otherwise indicated. Antibodies are described in detail in Sup-
plemental Table S1.
Plasmid construction and in vitro transcription
A 1.1-kb region of the Fam208a promoter (–1001 to +101
relative to transcription start site) was amplified with primers
5′GTCGAACTCGAGTAAATACTTTGGATGAAATTAG3′ and
5′GCTAACAAGCTTCGCACTCCAGCCACAGAGACG3′ using
mouse genomic DNA as the template. The fragment was digested
with XhoI and HindIII and inserted into pGL4.10[luc2] (Promega),
resulting in F208wt. This promoter region contains two E2F con-
sensus binding sequences (TTTCCCCGGGC and TTTGGCGGG).
Site-directed mutagenesis was conducted to sequentially mutate
the upstream site to TTTCCaattGC and the downstream site to
TTTttaaGG using QuickChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies, Santa Clara, California). The resulting
plasmid was named F208mut.
The coding regions of mouse Smarca4 and Smarcc1 were
amplified from pMX-Brg1 (Addgene plasmid #25855) and pMX-
Baf155 (Addgene plasmid #25856), gifts of Hans Schöler [23].
The primers used were 5′GGGCTTGTCGACGCCACCATGTC
TACTCCAGACCCACCCTTTG3′ and 5′GCTCAATCTAGAT
TCAGTCTTCCTCACTGCCACTTCCTG3′ (Smarca4) and 5′
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GGCTTCTCGAGGCCACCATGGCCGCGACAGCGGGTGGCG3′
and 5′ GGTCAAACTAGTCTACTTACACATGCCGTTTGGTG3′
(Smarcc1). The PCR products were ligated into the Sal1 and
Xba1 sites of a modified pIVT plasmid [24]. Following DNA
sequence confirmation, in vitro transcription was carried out using
AmpliCap-Max T7 High Yield Message Maker Kit (CELLSCRIPT,
Madison, WI).
Oocyte and embryo collection, culture, and
microinjection
GV-intact oocytes were collected from female mice 48 h follow-
ing injection with 5 IU equine CG (Calbiochem, San Diego, CA).
The cumulus cells were removed mechanically and the oocytes were
cultured in minimal essential medium alpha (MEMα; Invitrogen,
Carlsbad, CA) containing 2.5 µM milrinone to prevent GV break-
down. Following microinjection, oocytes were matured for 16 h
in MEMα containing 5% fetal calf serum. Metaphase II-arrested
eggs were collected from the oviducts of female mice superovu-
lated using 5 IU equine CG followed 48 h later with 5 IU hu-
man CG (hCG) (Calbiochem) at 13–14 h following hCG admin-
istration. Cumulus cells were removed using 0.1% hyaluronidase.
One-cell embryos were collected from superovulated, mated fe-
males at 15–16 h following hCG administration. The collection
medium was either Hepes-buffered Whitten medium [25] or Lei-
bovitz L-15 medium (Invitrogen) supplemented with 1% fetal calf
serum. Microinjections were performed using a Leica DMI 6000B
inverted microscope equipped with a XenoWorks micromanipu-
lator system and PrimeTech PMM-150FU piezo drill (Sutter In-
struments, Novato, CA). One-cell embryo injections were com-
pleted prior to 18 h following hCG injection. GV-intact oocytes
and embryos were injected into the cytoplasm with 5–10 pl
of a 1.5-mM pipette concentration of the following morpholino
oligonucleotides (5′ to 3′): Scr-MO, CCTCTTACCTCAGTTA-
CAATTTATA; Med13UTR-MO, GCCACAACCCACCATCCGC-
CATTAC; Med13-MO, CGTTCGACACGAAGGAGGAACTCAT;
or Med13L-MO, TCATGGTCCTCCGCGAGCCC (GeneTools,
Philomath, OR). Smarca4 and Smarcc1 cRNAs were microinjected
with Med13-MO at a final pipette concentration of 0.25 pg/pl each.
Embryos were cultured in KSOM medium (EMD Millipore, Biller-
ica, MA; cat. no. MR-106-D) in a humidified atmosphere of 5%
CO2, 5% O2, and 90% N2.
RNA isolation and real-time RT-PCR
For most experiments, total RNA was isolated from 50 oocytes,
eggs, or embryos using the PicoPure RNA Isolation kit (Thermo
Fisher Scientific, Waltham, MA). Enhanced GFP (eGFP) cRNA was
transcribed in vitro from pIVT-eGFP [26], and 1 ng was added to
each sample prior to RNA isolation as an internal control. Real-
time RT-PCR was performed as previously described [27], using
cDNA from two oocytes or embryos per reaction. All E2f transcripts
were amplified from the same three sets of GV oocytes to enable
comparison of Ct values. Relative gene expression was calculated
using the "Ct method [28] with eGFP expression for normalization.
For testing embryos for the presence or absence of Med13 floxed
exons 7–8, total RNA was isolated as above from a pool of 10
morula stage embryos from two mice/group, N = 2 pools/genotype.
Real-time RT-PCR was performed using cDNA from one morula per
reaction. Expression of Med13 exons 7–8 was calculated relative to
expression of Med13 exons 29–30 in the same sample using the
"Ct method [28]. Primer sequences are provided in Supplemental
Table S2.
Immunofluorescent staining, microscopy, and
quantification
For MED13 staining, embryos were fixed in ice-cold methanol for 10
min, then blocked overnight at 4◦C in blocking buffer (PBS, 3 mg/ml
BSA, 0.01% Tween-20) supplemented with 10% fetal calf serum.
Embryos were then incubated in primary anti-MED13 antibody
(Santa Cruz, Dallas, TX, sc-5369; 10 µg/ml) for 1 h at room tem-
perature (RT) followed by Alexa Fluor 488 anti-goat IgG (Thermo
Fisher Scientific, cat# A-11055; 2 µg/ml) for 1 h at RT. For γ H2AX
staining, embryos were fixed in 4% paraformaldehyde for 30 min,
permeabilized in 0.1% Triton X-100 for 20 min, then incubated in
blocking buffer for 1 h. Embryos were incubated in primary γ H2AX
antibody (Bioworld Technology, St Louis Park, MN; BS4760;
5 µg/ml) at 4◦C overnight followed by Alexa Fluor 555 anti-
rabbit antibody (Thermo Fisher Scientific, cat# A-21429; 2 µg/ml)
for 1 h at RT. For MED13L staining, embryos were fixed in 2%
paraformaldehyde for 40 min, permeabilized as above, then washed
in blocking buffer. Embryos were incubated in primary MED13L
antibody (Bethyl Laboratories, Montgomery, TX, A302-421A;
10 µg/ml) at 4◦C overnight followed by Alexa Fluor 555 anti-rabbit
antibody (Thermo Fisher Scientific, cat# A-21429; 4 µg/ml) for 1 h at
RT. For NANOG staining, embryos were fixed in 4% paraformalde-
hyde for 30 min, permeabilized in 0.1% Triton X-100 for 20 min,
then incubated in blocking buffer for 1 h. Embryos were incubated in
primary NANOG antibody (R&D Systems, Minneapolis, MN, cat#
AF2729; 10 µg/ml) at 4◦C overnight followed by Alexa Fluor 647
anti-goat IgG (Thermo Fisher Scientific, cat# A-21447; 4 µg/ml) for
1 h at RT. Terminal deoxynucleotidyl transferase dUTP Nick-End
Labeling (TUNEL) was performed as described previously [29] us-
ing the In Situ Cell Death Detection Kit, Fluorescein (Sigma-Aldrich)
except that 1.5 µg/mL DAPI was in the mounting medium. Peroxide-
treated embryos served as positive controls [29]. For some experi-
ments, zona pellucidae were removed immediately prior to fixation
using acid Tyrode medium.
For cell counts, blastocysts were fixed 120 h after hCG injec-
tion in 2% paraformaldehyde for 40 min, permeabilized as above,
then washed in blocking buffer. Embryos were incubated in primary
anti-CDX2 antibody (Abcam, Cambridge, MA; ab157524; 1 µg/ml)
at 4◦C overnight followed by primary OCT-3/4 antibody (Santa
Cruz, Dallas, TX; sc-8628; 10 µg/ml) for 1 h at RT. The embryos
were then washed and incubated with Alexa Fluor 488 donkey anti-
mouse (Thermo Fisher Scientific, cat# A-21202; 4 µg/ml) and Alexa
Fluor 555 donkey anti-goat (Thermo Fisher Scientific, cat# A-21432;
4 µg/ml) for 1 h at RT.
All oocytes and embryos were mounted in Vectashield contain-
ing 1.5 µg/mL DAPI (Vector Laboratories, Burlingame, CA), and
slides were scanned using a Zeiss LSM 510 UV confocal microscope.
Immunofluorescence signals were quantified using ImageJ software.
For EU, EdU, and γ H2AX staining, a region of interest was drawn
around each nucleus and the average pixel intensity was determined.
The values for each nucleus were then averaged to generate an in-
tensity level for each embryo. Intensity was expressed relative to the
average intensity of the control embryos for each independent ex-
periment. Quantification of CDX2, OCT4, and NANOG staining
intensity was done from confocal z-stack scans through entire blas-
tocysts followed by automated measurement of signal intensity in
each slice using ImageJ. The total image intensity was calculated by
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multiplying the overall average intensity by the number of images
in the stack. Quantification of blastocyst inner cell mass (OCT4-
positive), trophectoderm (CDX2-positive), and total cells (DAPI)
was performed manually after scanning a z-stack of images through
the full depth of each embryo. Total cell numbers were counted after
encoding nuclear depth using a rainbow look-up table as described
previously [30].
Immunoblot analysis
Immunoblot analyses for cyclin B1 and actin were performed as
described previously [31].
DNA replication, transcription, and luciferase assays
Embryos were cultured in KSOM with 10 µM 5-ethynyl-2′-
deoxyuridine (EdU) or 1 mM ethynyl uridine (EU) for 1 h and fixed in
4% paraformaldehyde in PBS for 30 min at RT. Edu or EU incorpo-
ration into DNA or RNA, respectively, was detected using Click-iT
EdU Alexa Fluor 488 Imaging Kit or Click-iT RNA Alexa Fluor
488 Imaging Kit (both from ThermoFisher, Waltham, MA) accord-
ing to the manufacturer’s protocols. Fluorescence was detected on
a Zeiss confocal microscope (Zeiss LSM 510 UV), and fluorescence
intensity was quantified using ImageJ software [32] as described
previously [33]. For luciferase assays, 1–2 pl of 50 000 copies/pl
plasmid DNA was microinjected into the male pronucleus us-
ing a pressure-controlled digital microinjector (Sutter Instruments).
The injected plasmid DNA was a 1:1 mixture (13.3 ng/µl each)
of TK-ren with either F208wt or F208mut firefly luciferase plas-
mids. Plasmid DNA injections were performed 25 h following hCG
administration; for doubly injected embryos, this was 9 h follow-
ing morpholino injections. Following plasmid injection, the embryos
were cultured in KSOM containing 2 µg/ml aphidicolin to inhibit
DNA replication. Luciferase assays were performed 24 h later using
the Dual-Luciferase Reporter Assay System (Promega) according to
the manufacturer’s instructions. Firefly luciferase activity was nor-
malized using renilla luciferase activity from the same embryo.
RNA sequencing and analysis
Total RNA was isolated from 4 independent collections of 40 em-
bryos/group using the PicoPure RNA Isolation Kit (Thermo Fisher
Scientific) and amplified using Ovation RNA-Seq System V2 (Nu-
GEN, San Carlos, CA). mRNA libraries were constructed from
400 ng cDNA using Illumina TruSeq RNA Sample Prep Kits, version
2. The cDNA was first fragmented using a Covaris E210 focused ul-
trasonicator. Library amplification was performed using 12 cycles
to minimize the risk of overamplification. Unique barcode adapters
were applied to each library. Libraries were pooled in equimolar ra-
tio and sequenced together on an Illumina HiSeq 2000 with version
3 flow cells and sequencing reagents. At least 15 million 101-base
read pairs were generated for each individual library. Data were pro-
cessed using RTA 1.13.48 and CASAVA 1.8.2 (Illumina, San Diego,
CA). Data were deposited in the NCBI GEO database, accession
number GSE90710.
To identify differentially expressed transcripts, raw sequence
reads were mapped to mouse cDNA sequences using BWA (ver.
0.7.12) [34], with the default setting of its BWA-MEM algorithm
paired-end read mapping protocol. The cDNA sequence library used
for the mapping included all transcripts in the mm10 GENCODE
comprehensive gene annotation (http://www.gencodegenes.org/).
The mapping was done separately for each replicate. Differentially
expressed transcripts were identified using the improved version
of EpiCenter [35], which considers both read coverage depth and
within-group variation of read counts for testing significance of gene
expression change between groups. Specifically, we first filtered out
all reads that were not mapped in-pair to the reference cDNA se-
quences, and then counted reads mapped to each cDNA sequence.
Read counts in each biological replicate were then normalized so that
the average number of total mapped reads was same across all repli-
cates in both groups. To increase the reliability of the log ratio data
used in statistical testing, any transcript with a mean of normalized
counts less than 100 in both groups was removed from further analy-
sis. This filter also allowed us to focus on genes with more than min-
imal levels of expression. The significance cutoff was set at 5% false
discovery rate (FDR) based on the Benjamini–Hochberg method.
The generation of heatmap plots of all differentially expressed tran-
scripts, and hierarchical clustering analysis of seven RNAseq samples
were carried out using R (https://www.r-project.org) statistical lan-
guage with the gplots package.
Differentially expressed transcripts were submitted to DAVID
(https://david.ncifcrf.gov) for gene enrichment analysis in all gene
ontology (GO) terms and pathways. This was done separately for
upregulated and downregulated transcripts. The analysis of tran-
scription of repeats was performed separately. In this analysis, all raw
reads were mapped to the whole mouse genome reference (mm10)
using Tophat2 [36], and EpiCenter was used to do comparison anal-
ysis of transcription levels of repeat regions between the two groups.
All repeat regions and repeat types were based on the annotation
from the UCSC rmsk table downloaded from the UCSC genome
browser. The cutoff for differentially transcribed repeat regions was
set at 5% FDR based on the Benjamini–Hochberg method.
Differential motif enrichment analysis of promoter
sequences
The 1-kb promoter sequences for the 1054 downregulated genes
and 664 upregulated genes were extracted using the mouse reference
gene annotation (mm10). The total numbers of unique promoter se-
quences obtained were 923 and 654, respectively; these sequences
were referred to as foreground sequences. For each promoter se-
quence in each dataset, we randomly selected 10 promoter sequences
of the same length (1 kb) with similar C/G content from the entire
mouse genome to serve as the matched background sequences. We
then scanned each set of the foreground promoter sequences and the
corresponding background sequences [37] for putative transcription
factor-binding sites using motif models from TRANSFAC, JASPAR,
and UniPROBE [38–40]. A total of ∼ 1300 motif models were used
in the analysis. For each motif model, we counted the number of
foreground sequences and background sequences containing at least
one predicted site for the motif. Motif enrichment analysis was then
carried out on the resultant 2 × 2 contingency table using Fisher
exact test.
Conditional knockout mouse breeding and embryo
development assays
For litter size analysis, Med13f/f females were mated to Med13f/f
males (three pairs) and Med13f/f; ZP3-Cre females were mated to
Med13f/△ males (seven females, five males) for 6 months. The cages
were monitored daily, and litter sizes from each group were recorded.
For parthenogenetic activation, MII eggs were collected from su-
perovulated females and then activated for 6 h in 10 mM SrCl2
in Ca2+-free CZB medium [41] containing 5 µg/ml cytochalasin B
or 2 µg/ml cytochalasin D to prevent second polar body emission.
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Figure 1. MED13 knockdown inhibits preimplantation embryo development. (A) Expression of Med13 mRNA in oocytes and preimplantation embryos relative
to that in GV oocytes. N = 3. (B) Expression of Med13 mRNA in late 2C embryos cultured without (C, control) or with α-amanitin (α-am) starting at the 1C stage
to block zygotic transcription. N = 3; ∗P ≤ 0.05, T-test. (C) MED13 protein in oocytes, eggs, and 1C, 2C, and 4C-stage embryos. Bar = 20 µm. N = 3, total of
11–25/group. (D) MED13 protein in 4C-stage embryos following microinjection at the 1C stage using the indicated morpholino. Bar = 20 µm. Graph indicates
relative signal intensity in nuclei. N = 3, total of 47–53/group; ∗P < 0.05, T-test. (E) Representative DIC images of embryos 3 days following microinjection at
the 1C stage using the indicated morpholino. (F) Percentage of embryos to reach the various preimplantation embryo stages following microinjection at the 1C
stage with the indicated morpholino. Bar = 80 µm. N = 4, 16–37 1C embryos/group for each replicate; ∗P ≤ 0.05 compared to Scr-MO control at the same time
point, ANOVA with Holm-Sidak multiple comparisons test. All graphs show mean ± s.e.m. Abbreviations used in this and all subsequent figures: ooc, GV-intact
oocyte; egg, MII-arrested egg; 1C, one-cell embryo; 2C, two-cell embryo; 4C, four-cell embryo; 8C, eight-cell embryo; mo, morula; bl, blastocyst.
In vivo-fertilized 1C embryos were collected from either sponta-
neously cycling or superovulated females mated to males overnight
and found to be vaginal plug-positive the following morning. All em-
bryos were cultured in KSOM at 37◦C in a humidified atmosphere
of 5% CO2, 5% O2, and 90% N2 and development was monitored
daily. Postimplantation embryo development was assayed by mat-
ing Med13f/f or Med13f/f;ZP3-Cre females to Med13f/△ ;Hspa2-Cre
males. The females were sacrificed on E12.5, and the number of
viable and nonviable implantation sites was recorded.
Statistical analysis
All analyses were performed using GraphPad Prism software. Com-
parisons of two groups were performed using two-tailed T-tests,
with Welch correction in case of unequal standard deviations. Mul-
tiple group results were analyzed using ANOVA with Holm-Sidak
multiple comparisons test. A two-tailed Fisher exact test was used
to compare numbers of viable and nonviable implantation sites. De-
tailed information is included in the figure legends.
Results
To determine which mediator complex components were recruited
for translation during oocyte maturation, we utilized a published mi-
croarray dataset that identified transcripts associated with polysome
fractions isolated from mouse oocytes at different stages of matu-
ration [1]. Three kinase domain proteins were the most highly re-
cruited mediator mRNAs. Med13 was increased more than 11-fold,
whereas Med13l and Med12l were increased about 9- and 8-fold,
respectively, suggesting that these mRNAs were strongly recruited
for translation during oocyte maturation. Relative to its expression
in oocytes, Med13 mRNA levels remained relatively stable through
the 2C stage (Figure 1A). To determine if Med13 was transcribed
very early from the embryonic genome, we measured Med13 mRNA
expression in late 2C-stage embryos that were cultured beginning
at the 1C stage with or without α-amanitin to block transcription
[42]. Med13 mRNA levels were reduced to about one-third of that
in controls by α-amanitin treatment (Figure 1B), indicating that the
majority of the mRNA present in late 2C-stage embryos was a re-
sult of new transcription from the embryonic genome. Consistent
with these findings, MED13 immunoreactivity increased markedly
between the GV oocyte and MII egg stages, and was detected in
the cytoplasm of 1C embryos, but increased in 2C- and 4C-stage
embryos where it localized to the nuclei (Figure 1C).
These findings led us to hypothesize that MED13 is a very early
regulator of ZGA in mouse preimplantation embryos. To test this
hypothesis, we knocked down MED13 protein in 1C embryos by mi-
croinjecting morpholino oligonucleotides targeting the Med13 trans-
lation start site (Med13-MO) approximately 4 h after fertilization
in vivo. This procedure reduced MED13 protein levels as indicated
by immunofluorescence analysis (Figure 1D). Med13-MO-injected
embryos cleaved to 2C, but many became arrested after this point,
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Figure 2. MED13 knockdown inhibits embryo transcription and cell cycle progression. One-cell stage embryos were microinjected with the indicated morpholino,
then cultured to the 2C or 4C stage. (A) EU staining as an indicator of transcription levels. (B) Quantification of EU staining. N = 3, total of 23–24 embryos/group;
∗P ≤ 0.05, T-test. (C) EdU staining as an indicator of DNA replication. (D) Quantification of EdU staining. N = 3, total of 20–24 embryos/group; ∗P ≤ 0.05, T-test. (E)
Gamma H2AX staining as an indicator of DNA double strand breaks. (F) Quantification of γ H2AX staining. N = 4, total of 14–36 embryos/group; ∗P ≤ 0.05, T-test.
(G) Immunoblot analysis of cyclin B1 in late 2C-stage embryos (upper panel). Actin was used as a loading control (lower panel). Numbers indicate apparent
Mr × 10−3. Lysate of 20 embryos in each lane. Blot is representative of N = 3 independent replicates. All graphs show mean ± s.e.m. All bars = 20 µm.
with only ∼ 40% of the embryos developing to the four-cell (4C)
stage, and none beyond 4C (Figure 1E and F). In contrast, when 1C
embryos were microinjected with the MED13-MO starting 6 h after
fertilization in vivo, when pronuclei had already formed, there was
far less impact on preimplantation embryo development, with 78%
(54/69) progressing to the morula stage, though only 13% (9/69) de-
veloped into blastocysts. Embryos injected with a scrambled control
morpholino (Scr-MO) served as negative controls. We generated
capped, polyadenylated mRNA encoding full-length MED13 pro-
tein, with or without either V5, GFP, or mCherry tags on either end,
but following microinjection of these mRNAs into 1C embryos, we
were unable to observe expression of the exogenous mRNA despite
no difficulties in expressing many other positive control proteins.
For this reason, we could not perform a standard rescue experiment
to rule out off-target effects of the Med13-MO. As one alterna-
tive approach, we tested the effect of microinjecting a morpholino
that targeted a region of the Med13 5′ UTR (Med13UTR-MO). Like
the Med13-MO-injected embryos, the Med13UTR-MO-injected em-
bryos had significantly arrested development starting at the 4C stage,
though a few developed into morulae (Figure 1F). These results sug-
gested that translation of MED13 after fertilization was essential for
preimplantation embryo development.
To determine whether MED13 knockdown caused embryo de-
velopment arrest because of a global failure of transcription, total
transcriptional activity in Med13-MO-injected embryos was mea-
sured using the uridine analog 5-EU [43]. Despite the finding that
many of the embryos arrest at the 2C stage, there was no detectable
difference in overall transcriptional activity of MED13 knockdown
embryos until the 4C stage (Figure 2A and B). These findings sug-
gested that MED13 knockdown did not disrupt global function of
the mediator complex. Another explanation for embryo develop-
mental arrest was a failure of DNA replication. DNA replication
was measured using EdU [44]. MED13 knockdown embryos at the
2C stage had significantly increased EdU staining intensity compared
to Scr-MO-injected embryos indicating successful DNA replication,
whereas 4C embryos had very low EdU incorporation (Figure 2C
and D). In addition, Med13-MO-injected embryos had evidence of
increased DNA double strand breaks at the 4C stage as indicated
by γ H2AX nuclear staining (Figure 2E and F). To determine if the
Med13-MO-injected embryos arrested before or after entering M
phase, we performed immunoblot analysis of cyclin B1 protein. Cy-
clin B1 was dramatically lower in Med13-MO-injected 2C embryos
as compared to controls (Figure 2G). We conclude from these exper-
iments that a failure of DNA replication cannot explain the devel-
opmental arrest that occurs at the 2C stage, and that loss of MED13
causes cell cycle arrest prior to M phase.
Based on findings that many mediator subunits regulate tran-
scriptional activation or repression of specific developmental path-
ways [45], we tested the idea that MED13 functions to regulate
the transcription of a subset of genes during ZGA. This was done
by microinjecting either Scr-MO or Med13-MO at the very early
1C stage and then performing RNA sequencing (RNAseq) following
culture to the late 2C stage. Of the four independent replicates per
group, one replicate from the Scr-MO group failed quality control,
leaving three Scr-MO and four Med13-MO replicates for analysis.
Unsupervised hierarchical analysis revealed clearly distinct sorting
by treatment group (Figure 3A). Analysis of these data using the
GENCODE comprehensive dataset [46] and a FDR of 5% revealed
significant changes in transcription of protein-coding genes, noncod-
ing RNAs, and repetitive elements (Figure 3B; see also Supplemental
Table S3). Compared to the Scr-MO controls, expression of 3404
transcripts was altered in the Med13-MO-injected embryos, with
1201 (35%) upregulated and 2203 (65%) downregulated. Almost
twice as many genes were downregulated, suggesting that MED13
is required for transcriptional activation at more gene loci than for
transcriptional repression. Of note, there was no evidence of positive
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Figure 3. MED13 knockdown impairs transcription of genes required for the OET, including cell cycle and chromatin-remodeling proteins. One-cell stage embryos
were microinjected with the indicated morpholino, then cultured to the late 2C stage. RNA sequencing was performed on independent pools of 40 embryos per
group. (A) Unsupervised hierarchical clustering of gene expression differences in Scr-MO (Scr)- and Med13-MO (M13)-injected embryos. (B) Numbers of altered
transcripts of the indicated types in Med13-MO-injected embryos relative to Scr-MO-injected embryos. (C) Highly significant GO biological categories of genes
downregulated in Med13-knockdown embryos. Numbers to right of bars indicate number of genes in category. (D) Selected GO cell cycle genes significantly
altered in Med13-knockdown embryos. (E) Selected GO chromatin modification genes significantly altered in Med13-knockdown embryos. (F) Percentage of
embryos to reach the indicated preimplantation embryo stages following microinjection at the 1C stage with the either Scr-MO, Med13-MO, or Med13-MO and
both Smarca4 and Smarcc1 mRNAs. N = 3, 8–12 1C embryos/group for each replicate; ∗P ≤ 0.05 compared to Scr-MO control at the same time point, #P ≤ 0.05
compared to MED13-MO at the same time point, ANOVA with Holm-Sidak multiple comparisons test. Graph shows mean ± s.e.m. (G) Graph showing total
number of chromosomal regions either up- or downregulated for each of the indicated repetitive element classes.
TUNEL staining in either injection group at the late 2C stage (data
not shown), and the RNAseq data revealed no alterations in tran-
scription or splicing of Trp53 or its downstream target Cdkn1a (en-
coding p21/WAF1/CIP1) in the knockdown embryos. These findings
indicate that the potential off-target effect of p53-induced apoptosis
had not occurred [47].
GO pathway analysis of the altered genes (5% FDR) was per-
formed separately for both upregulated and downregulated genes.
A nonredundant set of highly significant pathways (Benjamini–
Hochberg adjusted P ≤ 0.05) was manually sorted into categories.
The categories for genes upregulated in response to MED13 deple-
tion were in general far less significantly altered than the down-
regulated genes, but included nucleotide binding, cancer, signaling,
and cytoskeleton (see Supplemental Table S4). The downregulated
gene categories included RNA processing, protein catabolism, cell
cycle, transcription, chromatin modification, and DNA repair (Fig-
ure 3C; see also Supplemental Table S5). These specific downregu-
lated gene categories and their high degree of significance suggested
that MED13 was preferentially involved in activating transcription
of genes that control pathways previously identified to be critical
for the success of the OET [48]. Notably, the list of significantly
altered cell cycle genes included a large number of genes either
documented as or anticipated to be critical regulators of preim-
plantation embryo development, including Wee2, Brca2, Ccnb1,
Chek2, Cdc25a, and Cdc45 (Figure 3D). Similarly, the significantly
downregulated chromatin modifying genes included several identi-
fied as essential for preimplantation embryo development, includ-
ing Smarca4 (previously Brg1), Hira, and Hdac1 [7, 49, 50] (Fig-
ure 3E). Furthermore, Smarca4 and another significantly downregu-
lated gene, Smarcc1 (previously Baf155), encode subunits of the BAF
(Brg/Brahma-associated factors) ATP-dependent chromatin remod-
eling complex known as esBAF, which is required for postimplanta-
tion embryo development as well as embryonic stem cell self-renewal
and pluripotency [51–53].
To determine whether the reductions in mRNAs encoding the es-
BAF components SMARCA4 and SMARCC1 were responsible for
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the embryo arrest phenotype in MED13-knockdown embryos, we
microinjected mRNAs encoding both of these proteins into zygotes
along with the MED13-MO. This manipulation doubled the success
of development of MED13-knockdown embryos to the 4C stage, but
did not promote their development beyond this point (Figure 3F).
These findings indicate that MED13 is a critical upstream regulator
of the OET in part via its effect on transcription of esBAF compo-
nents.
Consistent with previous reports [11, 12], we found that long-
terminal repeats (LTRs) were highly abundant in the RNAseq
datasets, comprising >75% of the repetitive element transcripts
expressed in 2C embryos in both the SCR-MO and MED13-MO
groups. Depletion of MED13 caused significant alterations in spe-
cific repeat classes. There was a dramatic increase in the number
of mouse transcript (MT)-type LTRs as a result of upregulation of
MT transcripts from many different chromosomal regions; only a
few MT regions were downregulated (Figure 3G). Given the roles
of dicer 1 and argonaute 2 in degrading MT retrotransposons in
oocytes [54, 55], this finding is consistent with our RNAseq data
showing downregulation of Dicer1 by 1.6-fold and Ago2 by 1.9-
fold. In contrast, two other LTR transcript types, ERVK and ORR1,
as well as several non-LTR transcript types, were downregulated in
more repeat regions following MED13 depletion.
We next asked whether MED13 was interacting with specific
transcription factors to regulate expression of the altered mRNAs.
We analyzed the promoter sequences of protein-coding genes iden-
tified as significantly altered in our RNAseq dataset; promoters of
upregulated and downregulated genes were analyzed separately. For
each promoter from an altered gene, 10 additional promoters with
similar GC content were randomly selected to serve as controls.
This analysis identified several transcription factor-binding motifs
that were strongly associated with the promoters of significantly
downregulated genes (Table 1). In particular, multiple motifs that
bind E2F family winged-helix transcription factors were identified
as highly enriched. Indeed, E2f1, E2f2, and E2f5 transcripts were
relatively abundant in fully grown GV oocytes (Supplemental Table
S6), suggesting the presence of the corresponding proteins in early
embryos.
To determine whether the E2F-binding sites in gene promoters
were necessary for transcriptional regulation by MED13, we per-
formed luciferase assays using the promoter region of Fam208a.
This gene was selected because in MED13-knockdown embryos it
was downregulated by 4.1-fold from the RNAseq assay, was vali-
dated as a downregulated gene by quantitative real-time PCR (down
3.1-fold ± 0.08 s.e.m.), and contained two predicted E2F-binding
sites in the proximal promoter. A plasmid construct was generated
in which the region from –1000 to +100 relative to the transcrip-
tion start site of Fam208a was cloned in front of firefly luciferase
(F208wt; Figure 4A). A second construct was generated with the
same promoter region but the two predicted E2F sites were mu-
tated (F208mut; Figure 4A). A plasmid containing renilla luciferase
driven by the TK promoter (TK-ren) was used as a control for the
pronuclear microinjection procedure. The control TK-ren plasmid
was mixed at a 1:1 molar ratio with either the F208wt or F208mut
plasmids, and the mixture was microinjected into the male pronu-
cleus of each 1C embryo. The embryos were then cultured for 24 h in
the presence of aphidocolin to prevent DNA replication and allow ef-
ficient transcription of the microinjected plasmids (Figure 4B) [56].
The firefly and renilla luciferase signals were then read from each
embryo and expressed as a ratio (firefly luciferase/renilla luciferase).
Mutation of the E2F sites caused luciferase activity to decrease to
about 25% of that from the wild-type construct, indicating that the
E2F-binding sites were required for efficient luciferase transcription
from the Fam208a promoter (Figure 4C). We next tested whether
this promoter required MED13 for efficient transcription. Early 1C-
stage embryos were microinjected with either Med13-MO or Scr-
MO, cultured for 9 h to allow protein knockdown, and then the
same embryos were injected with the luciferase constructs into the
male pronucleus (Figure 4D). MED13-knockdown embryos had sig-
nificantly lower transcription from the F208wt plasmid than the Scr-
MO-injected embryos and similar transcription levels to that from
F208mut plasmid in MED13-knockdown embryos (Figure 4E). In
fact, transcription of F208wt in MED13-knockdown embryos was
similar to that of the F208mut plasmid in Scr-MO-injected embryos.
These findings indicated that the E2F-binding sites were required for
efficient MED13-mediated transcription from this promoter.
Based on the above findings, we predicted that oocytes com-
pletely lacking MED13 would not undergo successful preimplan-
tation embryo development unless rescued by a wild-type Med13
allele (Med13+) at fertilization. We generated female mice carry-
ing the ZP3-Cre transgene and homozygous for the Med13-floxed
allele [21] (Med13f/f;ZP3-Cre); ovulated eggs of these females will
carry two copies of a loss-of-function Med13 allele (Med13"/").
These mice were mated to Med13f/" males, and the resulting off-
spring were genotyped. As anticipated, the litter sizes were reduced
as compared to those of controls (Figure 5A), and 100% of the off-
spring of Med13f/f;ZP3-Cre females were Med13f/", indicating that
Med13"/" embryos did not survive to delivery. To determine the ef-
ficiency of preimplantation embryo development in embryos lacking
MED13, we collected Med13"/" and Med13f/f eggs and partheno-
genetically activated them to avoid generation of heterozygous em-
bryos. Of note, parthenogenetic activation, particularly when per-
formed with strontium to induce repetitive calcium oscillations
and cytochalasin to maintain a diploid chromosome complement,
results in embryos practically indistinguishable from normally fer-
tilized embryos until the blastocyst stage or later [57–60]. Acti-
vated Med13"/" eggs, unlike Med13-MO-injected 1C embryos, de-
veloped beyond the 4C stage but had far lower development to
the morula and blastocyst stages than activated Med13f/f eggs (Fig-
ure 5B). Furthermore, the total number of cells in the Med13"/"
embryos that did reach the blastocyst stage was significantly reduced
(Figure 5C). The abnormal but improved development of Med13"/"
eggs following parthenogenetic activation compared to Med13-MO-
injected 1C embryos suggested that Med13"/" eggs had partially
compensated for loss of MED13 during oocyte growth within the
ovarian follicle.
To better characterize the preimplantation development pheno-
type of embryos lacking MED13, we generated male mice in which
Med13 was conditionally deleted only in sperm using the Hspa2-
Cre transgene [22]. This transgene efficiently deleted the targeted
allele because when Med13f /f;Hspa2-Cre males were mated to wild-
type females, 100% of the offspring were Med13+/" (31/31 pups
from three litters). Med13f/";Hspa2-Cre males were then mated to
either Med13f /f or Med13f /f;ZP3-Cre females to generate Med13f/"
or Med13"/" embryos. In contrast to the parthenogenetically acti-
vated embryos, the in vivo-derived Med13"/" 1C embryos developed
efficiently in vitro to the blastocyst stage (Figure 5D). Because of this
difference in phenotype, we performed RT-PCR and confirmed ef-
ficient deletion of the floxed exons (7–8) in the Med13"/" embryos
(Figure 5E). The total number of cells in Med13"/" blastocysts was
reduced compared to controls, with the difference in cell numbers
explained by a reduction in the number of trophectoderm cells as
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Table 1. Top 20 significantly enriched motifs in the promoters of genes downregulated in MED13-knockdown embryos.
indicated by CDX2 labeling (Figure 5F and G). Although the expres-
sion levels of both CDX2 and OCT4 were no different in the two
groups of blastocysts, expression of NANOG was reduced by ∼ 40%
in Med13"/" embryos as compared to Med13f /f as indicated by a con-
sistent reduction in immunofluorescence intensity (Figure 5H and I).
To determine how far Med13"/" embryos developed, the same mat-
ing was done and maternal weights were followed from E0.5 to
E15.5. All pregnant females carrying Med13"/" embryos lost weight
between E8.5 and E12.5, indicating that their pregnancies were dis-
rupted by this time. Examination of E12.5 uteri for the number of
resorption sites indicated that Med13"/" embryos implanted as fre-
quently as control Med13f/" embryos but did not survive to E12.5
(Figure 5J).
We hypothesized that the successful preimplantation embryo de-
velopment and implantation of Med13"/" embryos, in contrast to
the early cleavage stage development arrest observed in the Med13-
MO-injected embryos, might be explained by compensatory upreg-
ulation of the MED13 paralog, MED13L. The ZP3-Cre transgene is
expressed and excises floxed alleles during the relatively long phase of
oocyte growth within the ovarian follicle [20], so there is a significant
period of time when oocytes are transcriptionally active and could in
theory compensate for a deleted protein. In wild-type mice, MED13L
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Figure 4. E2F transcription factor binding motif mediates MED13-dependent
gene transcription. (A) Schematic diagram of luciferase plasmids showing
wild-type and mutated E2F-binding motifs in the Fam208a promoter. Num-
bers indicate position relative to TSS (arrow). (B) Schematic of experimental
design for plasmid injections. (C) Relative luciferase activity following plas-
mid injection alone using F208wt or F208mut plasmids. N = 4, total of 23–26
embryos/group; ∗P ≤ 0.05, T-test. (D) Schematic of experimental design for
morpholino and plasmid injections. (E) Relative luciferase activity in embryos
first injected with the indicated morpholino and then 9 h later with the indi-
cated plasmid. N = 6, total of 21–22 embryos/group; ∗P ≤ 0.05 compared
to F208wt plasmid/Scr-MO group, ANOVA with Holm-Sidak multiple compar-
isons test. All graphs show mean ± s.e.m.
is expressed in GV oocytes, 1C, and 2C embryos, with predomi-
nant localization in the nuclei (Figure 6A). To determine if MED13L
was upregulated in oocytes lacking MED13, we compared MED13L
protein expression in Med13f/f and Med13"/" oocytes. MED13L
was upregulated ∼ 1.4-fold in Med13"/" oocytes (Figure 6B). We
next tested whether MED13L, like MED13, was required for suc-
cessful preimplantation embryo development. Wild-type GV stage
oocytes were injected with morpholino oligonucleotides targeting
the Med13l translation start site (Med13L-MO) and then matured
to MII and parthenogenetically activated. The resulting embryos had
reduced levels of MED13L protein at the late 1C stage, documenting
efficacy of the Med13L-MO (Figure 6C). We then injected wild-type
1C embryos with Med13L-MO approximately 4 h after fertilization
in vivo and monitored preimplantation development. Med13L-MO-
injected embryos had reduced efficiency of development to the blas-
tocyst stage as compared to Scr-MO-injected embryos (Figure 6D),
though most embryos arrested at the 8C-morula stage rather than at
the 2C–4C stage like Med13-MO-injected embryos, and a few devel-
oped to the blastocyst stage. These findings suggested that MED13
and MED13L were both required for successful preimplantation
embryo development, and that their functions did not overlap com-
pletely.
To determine if MED13L was compensating for MED13 func-
tions in Med13"/" early cleavage stage embryos, Med13"/" GV
oocytes were microinjected with Scr-MO or Med13L-MO, matured
in vitro, and then parthenogenetically activated. As a control for
morpholino specificity, additional Med13"/" oocytes were injected
with the Med13-MO, which should not affect their development
unless off-target effects are present. Med13"/" oocytes injected with
Scr-MO and Med13-MO developed to the blastocyst stage as well
as noninjected Med13"/" oocytes (Figure 6E). However, Med13"/"
oocytes injected with Med13L-MO arrested at the 2–4C stage, much
like wild-type 1C embryos injected with Med13-MO (compare Fig-
ure 6E to Figure 1F). These embryos also had a marked reduction in
transcriptional activity at the 4C stage, similar to wild-type embryos
injected with MED13-MO (Figure 6F). To further test the existence
of a compensating mechanism and to test for off-target effects of the
Med13-MO, Med13f/f, and Med13"/", metaphase II stage eggs were
parthenogenetically activated and then injected with Med13-MO
and allowed to develop in vitro. Consistent with our previous obser-
vations using wild-type embryos (Figure 1F), Med13-MO-injected
Med13f/f embryos arrested at the 2C to 4C stage (Figure 6G). In
contrast, Med13-MO-injected Med13"/" embryos developed to the
blastocyst stage, confirming that the Med13-MO does not have sig-
nificant off-target effects. Taken together, these findings suggest that
compensatory upregulation of MED13L in early cleavage stage em-
bryos allows Med13"/" embryos to survive long enough to form
blastocysts that implant, but that during preimplantation or early
postimplantation development, MED13 has critical functions that
are not compensated by MED13L.
Discussion
The data reported here demonstrate that MED13 is essential for
driving the OET in the mouse. Maternally generated Med13 mRNA
is recruited for translation during oocyte maturation. The resulting
protein specifically supports transcription of a set of genes required
for key aspects of the OET, including chromatin remodeling, RNA
processing, protein catabolism, cell cycle control, and DNA repair
[48]. This function does not appear to be a result of global effects on
transcription. Instead, MED13 interacts directly or indirectly with
specific transcription factors including those of the E2F family to
direct expression of a new set of genes from the zygotic genome,
including esBAF components, which facilitate reprogramming of the
zygote into a totipotent, developmentally competent preimplantation
embryo (Figure 7).
Initial reports indicated that the mediator kinase domain serves as
a transcriptional repressor by interfering with core mediator-RNA
polymerase II interactions; however, later studies reported that it
also functions in transcriptional activation [16]. For example, CDK8
phosphorylates the transactivation domain of STAT1 to both up-
and downregulate transcription of genes important for the inter-
feron signaling pathway [61]. CDK8 also promotes transcriptional
elongation of proximally paused HIF1A target genes in response to
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Figure 5. Postimplantation developmental arrest of Med13 knockout embryos. (A) Average litter size from breeding pairs of indicated genotypes. N = 10
litters/group, ∗P < 0.05, T-test. (B) Metaphase II eggs of the indicated genotype were parthenogenetically activated and allowed to develop in vitro. Graph
represents average percentage of embryos to develop to the indicated stages. N = 3, total of 51–55 1C embryos/group; P < 0.05 compared to same stage,
ANOVA with Holm-Sidak multiple comparisons test. (C) Total cell numbers in parthenogenetically activated embryos of each genotype that reached the blastocyst
stage. N = 27 embryos/group, ∗P < 0.0001, T-test. (D) In vivo fertilized, 1C-stage embryos of the indicated genotypes were collected and allowed to develop in
vitro. Graph represents percentage of embryos to develop to the blastocyst stage. N = 3 breeding pairs per group, 8–13 1C embryos collected per female. (E)
Relative expression of Med13 mRNA encoding exons 29–30 and 7–8. Graph shows median ± range. N = 2 replicates. (F) Representative immunofluorescent
staining of blastocyst stage embryos of the indicated genotypes that developed from the 1C stage in vitro. (G) Graph of cell numbers in the blastocysts from (E).
Inner cell mass (ICM), trophectoderm (TE). N = 3, total of 13–16 embryos/group; ∗P < 0.05, T-test. (H) Representative immunofluorescent staining of blastocyst
stage embryos of the indicated genotypes that developed from the 1C stage in vitro. Red channel on left, merged image on right. (I) Graph of NANOG staining
intensity in the blastocysts from (G). N = 3, total of 23–31 embryos/group; ∗P < 0.0001, T-test with Welch correction. (J) Females carrying oocytes with normal
amounts of MED13 (Med13f/f) or lacking MED13 (Med13f/f;ZP3-Cre) were mated to males carrying sperm lacking MED13 (Med13f/";Hspa2-Cre) to generate either
Med13f/" or Med13"/" embryos. Graph shows numbers of viable and nonviable implantation sites on E12.5. N = 4 females/group; ∗P < 0.0001, Fisher exact test.
All graphs except panel E show mean ± s.e.m. All bars = 20 µm.
hypoxia [62]. Here, we demonstrate that MED13 is required for
both transcriptional activation and repression during ZGA based
on our identification of both up- and downregulated transcripts in
MED13-knockdown embryos.
Because a global decrease in transcription was not detected in
2C-stage MED13-knockdown embryos, despite the fact that ∼ 60%
of these embryos arrested, it is unlikely that MED13 is required for
transcription of most genes at this stage. Similarly, the 2C-stage
embryo development arrest could not be explained by a failure
of DNA replication. However, an increase in DNA double strand
breaks was clearly evident in 4C-stage MED13-knockdown em-
bryos. This process probably began at the 2C stage based on the
significant downregulation of genes involved in DNA repair path-
ways detected by RNAseq, and may have contributed to the 2C-stage
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Figure 6. MED13L compensates for lack of MED13 during preimplantation embryo development. (A) Immunofluorescent staining of MED13L protein in wild-type
GV oocytes, 1C- and 2C-stage embryos. GV-control staining done with no primary antibody. (B) Immunofluorescent staining and quantification (arbitrary units)
of MED13L in GV oocytes of the indicated genotype. N = 3, total of 30/group; ∗P < 0.05, T-test. (C) Immunofluorescent staining and quantification (arbitrary
units) of MED13L in parthenogenetically activated 1C embryos following microinjection of the indicated morpholino at the GV stage. N = 3, total of 18/group;
∗P < 0.05, T-test. (D) Percentage of wild-type embryos to reach the various preimplantation embryo stages following microinjection at the 1C stage with the
indicated morpholino. N = 3, total of 61–70 1C embryos/group; ∗P < 0.05 compared to Scr-MO control at same time point, ANOVA with Holm-Sidak multiple
comparisons test. (E) Percentage of embryos derived from parthenogenetically activated eggs to reach the various preimplantation embryo stages following
microinjection at the 1C stage with the indicated morpholino. N = 4, 15–24 1C embryos/group for each replicate; ∗P < 0.05 compared to Scr-MO control at same
time point, ANOVA with Holm-Sidak multiple comparisons test. (F) Representative images of Med13"/" embryos microinjected with the indicated morpholino
and stained with EU at the 4C stage as an indicator of transcription levels. Graph shows quantification of staining intensity. N = 3–6 embryos/group; ∗P < 0.05,
T-test. (G) Percentage of embryos derived from parthenogenetically activated eggs of the indicated genotypes to reach the various preimplantation embryo
stages following microinjection at the 1C stage with Med13-MO. Graph represents average percentage of embryos to develop to the indicated stages. N = 3,
total of 56–59 1C embryos/group; ∗P < 0.05 compared to same stage, ANOVA with Holm-Sidak multiple comparisons test. All graphs show mean ± s.e.m. All
bars = 20 µm.
arrest. Although it would be satisfying to explain the 2C-stage ar-
rest based on disruption of one or just a few specific gene targets,
the degree to which pathways critical for the OET were disrupted
in the MED13-knockdown embryos (Supplemental Table S5) pre-
vents us from drawing such a conclusion. Instead, we attribute the
cell cycle arrest phenotype to the combined effects of disrupting
expression of cell cycle, DNA repair, and chromatin remodeling
protein components, many of which have been shown previously
to be required for successful preimplantation embryo development.
For example, Nfyb, which encodes an essential subunit of the NF-
Y transcription factor complex that establishes open chromatin at
specific promoter regions [63, 64], was downregulated 1.9-fold in
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Figure 7. Schematic illustrating function of MED13 and MED13L during the OET. MED13 serves as a crucial link between transcription factors (e.g., E2F family
and SP1), coactivators, and the main mediator complex. The mediator complex recruits RNA polymerase II and its accessory factors, resulting in transcription of
specific gene classes required for preimplantation embryo development. In the absence of MED13, its paralog MED13L partially compensates for this function.
MED13-knockdown embryos. NF-Y was shown recently to regu-
late chromatin opening in mouse 2C embryos during ZGA [65]. The
partial rescue of MED13-knockdown embryo development by over-
expressing esBAF components highlights the importance of MED13
function upstream of this critical regulator of preimplantation de-
velopment and pluripotency.
The much larger number of downregulated genes than those up-
regulated in MED13-knockdown embryos was mainly explained by
changes in transcription of protein-coding genes. In fact, when repeti-
tive elements were evaluated separately, there were more upregulated
transcripts than downregulated. By far, the most abundant repetitive
elements present in oocytes and 2C embryos were of the LTR class,
which represented more than 75% of repeat transcripts [11, 12, 66].
The MT-type LTRs accounted for the vast majority of upregulated
repeat regions in the MED13-knockdown embryos. MT transcripts
are degraded in oocytes by the combined activities of the RNAse III
enzyme, dicer 1, and the catalytic component of the RNA-induced si-
lencing complex, argonaute 2 [54, 55]. Our findings that transcripts
encoding both of these proteins were significantly downregulated,
coincident with a dramatic increase in MT transcripts, suggest that
as in oocytes, they are involved in degrading MT transcripts in preim-
plantation embryos.
Structural and biochemical analyses indicate that MED12 serves
as the central core to which MED13 and CCNC-CDK8 are bound,
and that both MED13 and MED12 tether the kinase domain to the
core mediator complex via interactions with several subunits (re-
viewed in [17]). These findings suggest that CCNC-CDK8 interac-
tions with core mediator depend strictly on the presence of an intact
4-subunit kinase module. In contrast, there is evidence in Drosophila
that the homologs of MED12 and MED13 may function indepen-
dently of CCNC and CDK8 in regulating transcriptional responses
important for specific developmental pathways [67–69]. Our data
do not delineate whether MED13 is functioning independently from
or as part of an intact kinase module in the mouse embryo. Based
on the presence of mRNA transcripts, all of the kinase module com-
ponents are expressed in mouse zygotes. There is a requisite role
for CDK8 as early as the zygote stage because homozygous null zy-
gotes (generated via a gene-trap strategy) do not survive [70]. The
specific function of CDK8 in zygotes is unknown, but this requisite
CDK8 functional activity could be supported by interactions with
residual, maternally generated MED13 protein still present in the
MED13-knockdown embryos.
E2F transcription factors appear critical for activating transcrip-
tion of genes required for the OET. This is not surprising given that
E2Fs have important roles in somatic cells regulating transcription
of genes needed for mitotic cell cycle progression, including com-
ponents of the DNA replication machinery [71]. Cell cycle-related
genes were highly enriched in the set of downregulated genes in
Med13-MO-injected embryos, suggesting that MED13 serves as an
important activator of E2F-mediated gene transcription in early em-
bryos and that it could serve this function in somatic cells as well.
In support of this idea, there is evidence for an interaction between
the mediator kinase domain subunit CDK8 and E2F1 in human col-
orectal cancer cells [72]. E2Fs are divided into two categories based
on their predominant effects on the cell cycle. In general, “activat-
ing” E2Fs, including E2F1, E2F2, and E2F3, activate transcription
of genes important for cell proliferation, whereas “repressive” E2Fs,
including E2F4 and E2F5, promote cell cycle exit and cellular dif-
ferentiation [71]. It was previously reported that MED13L interacts
with E2Fs to promote growth inhibition in cancer cells; this effect
was at least partially mediated by E2F5 [73]. As the activating E2Fs,
E2F1 and/or E2F2 are likely responsible for interacting with MED13
to promote expression of the genes downregulated in Med13-MO-
injected embryos.
Phenotypic differences between genetic mutants and “mor-
phants,” in which protein levels are knocked down, are often ob-
served and can be explained by compensatory activation of func-
tional protein networks rather than off-target effects [74]. We found
that MED13L can compensate for MED13 function during the OET
sufficiently to support embryo development to the blastocyst stage.
This is not surprising given their high homology (52% amino acid
identity, 67% similarity), and the observation that MED13L can sub-
stitute for MED13 to form a kinase module complex with MED12
and CCNC-CDK8 [19]. There is some evidence for functional
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compensation by other mediator kinase domain paralogs. For ex-
ample, both MED12 and MED12L bind the transcription factor
SOX10 in similar ways, suggesting that both proteins could medi-
ate SOX10-based transcriptional responses during myelination [75].
Similarly, CDK8 and CDK19 both directly interact with the his-
tone arginine methyltransferase, PRMT5, resulting in repression of
gene transcription in mammalian cells [76]. However, the embryonic
lethal knockout mouse phenotypes observed for Med12 [77], Cdk8
[70], and Med13 (reported here) indicate that there is not complete
functional redundancy for any of the kinase module paralogs. Our
future studies will focus on determining additional critical factors
that, like MED13, direct transcription of genes essential for repro-
gramming the zygote into a totipotent embryo.
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